Program
TQA3605
A development code. Also written as “TQA3605 tablets”, “TQA3605 tablets plus NAs” and “TQA3605 Tablets”.
In Sino Biopharmaceutical's pipeline, HBV衣壳蛋白抑制剂 (CAM)
. Its studies are mostly in Hepatitis B, Chronic, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 42 open or running | phase 3since Aug 28, 2026 | Nov 20, 2023 | Sep 2028phase 3 · NCT07797231 |
- Named in Sino Biopharmaceutical’s own pipeline as
TQA3605
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 20, 2023First study: phase 2 study in Hepatitis B, ChronicFirst studyNCT06150014 · 88 enrolled · China
- Oct 14, 2024Phase 2 study in HBV Infection With LLVNCT06644417 · 122 enrolled · China
- May 18, 2025Phase 2 study in Hepatitis B, ChronicNCT06990776 · China
- Aug 28, 2026Phase 3 study in Hepatitis B, ChronicPhase 3 reachedNCT07797231 · 930 planned · China
Ahead
- Sep 2028Primary completion: phase 3 study in Hepatitis B, ChronicNCT07797231
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“HBV衣壳蛋白抑制剂 (CAM)”the company's pipeline, read by Claude · source
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07797231Hepatitis B, Chronic · China | 3 | Not yet recruiting | Sep 2028 | 930 |
| NCT06990776Hepatitis B, Chronic · China | 2 | Withdrawn | Jul 17, 2025 | 0 |
| NCT06644417HBV Infection With LLV · China | 2 | Completed | Aug 25, 2025 | 122 |
| NCT06150014Hepatitis B, Chronic · China | 2 | Active, not recruiting | Dec 2025 | 88 |
How it is read
Names in the registry
- “TQA3605 tablets”, 2 entries
- “TQA3605 tablets plus NAs”, 1 entry
- “TQA3605 Tablets”, 1 entry
Codes read as this program: TQA3605.
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.